Podcasts
Listen to the latest hemonc news from international experts
The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
Top ASH 2025 updates in AML: redefining frontline therapy, menin inhibition, venetoclax-based triplets, & emerging immunotherapies
This VJHemOnc podcast highlights key acute myeloid leukemia (AML) updates from ASH 2025. Amir Fathi, MD, MPH, Massachusetts General Hospital, Boston, MA, discusses the Phase II PARADIGM study (NCT04801797) comparing azacitidine plus venetoclax with intensive chemotherapy in newly diagnosed, induction-eligible AML and updated KOMET-007 results (NCT05735184) in AML of ziftomenib combinations in relapsed/refractory (R/R) NPM1-mutated or KMT2A-rearranged AML.
Alexander Perl, MD, University of Pennsylvania, Philadelphia, PA, reviews the Phase I/II VICEROY study (NCT05520567) in newly diagnosed FLT3-mutated AML, Naval Daver, MD, MD Anderson Cancer Center, Houston, TX, presents Phase Ib/II pivekimab sunirine data (NCT04086264) and Wei-Ying Jen, MA, BM BCh, M Med, MRCP, FRCPath, shares Phase II SAVE results (NCT05360160) in newly diagnosed AML, and Mohammad Maher Abdul-Hay, MD, NYU Langone Health, New York City, NY, discusses early Phase I CLN-049 data (NCT05143996) in R/R AML.
Date: 30th January 2026
